1. Home
  2. SLRC vs PHAT Comparison

SLRC vs PHAT Comparison

Compare SLRC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLRC
  • PHAT
  • Stock Information
  • Founded
  • SLRC 2007
  • PHAT 2018
  • Country
  • SLRC United States
  • PHAT United States
  • Employees
  • SLRC N/A
  • PHAT N/A
  • Industry
  • SLRC Finance/Investors Services
  • PHAT Biotechnology: Pharmaceutical Preparations
  • Sector
  • SLRC Finance
  • PHAT Health Care
  • Exchange
  • SLRC Nasdaq
  • PHAT Nasdaq
  • Market Cap
  • SLRC 889.2M
  • PHAT 716.5M
  • IPO Year
  • SLRC 2010
  • PHAT 2019
  • Fundamental
  • Price
  • SLRC $16.43
  • PHAT $11.91
  • Analyst Decision
  • SLRC Hold
  • PHAT Strong Buy
  • Analyst Count
  • SLRC 6
  • PHAT 5
  • Target Price
  • SLRC $16.13
  • PHAT $16.40
  • AVG Volume (30 Days)
  • SLRC 149.7K
  • PHAT 1.1M
  • Earning Date
  • SLRC 08-05-2025
  • PHAT 08-07-2025
  • Dividend Yield
  • SLRC 9.98%
  • PHAT N/A
  • EPS Growth
  • SLRC N/A
  • PHAT N/A
  • EPS
  • SLRC 1.63
  • PHAT N/A
  • Revenue
  • SLRC $222,445,000.00
  • PHAT $114,039,000.00
  • Revenue This Year
  • SLRC N/A
  • PHAT $194.40
  • Revenue Next Year
  • SLRC $0.22
  • PHAT $103.23
  • P/E Ratio
  • SLRC $10.09
  • PHAT N/A
  • Revenue Growth
  • SLRC N/A
  • PHAT 1049.82
  • 52 Week Low
  • SLRC $13.64
  • PHAT $2.21
  • 52 Week High
  • SLRC $17.94
  • PHAT $19.71
  • Technical
  • Relative Strength Index (RSI)
  • SLRC 52.85
  • PHAT 75.25
  • Support Level
  • SLRC $16.26
  • PHAT $9.82
  • Resistance Level
  • SLRC $16.62
  • PHAT $11.19
  • Average True Range (ATR)
  • SLRC 0.22
  • PHAT 0.71
  • MACD
  • SLRC 0.02
  • PHAT 0.17
  • Stochastic Oscillator
  • SLRC 75.70
  • PHAT 94.07

About SLRC SLR Investment Corp.

SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: